Scientific deep-dive

Metformin for Weight Loss: How Much You Lose, With or Without Diabetes

Metformin takes off about 2% of body weight on average in people without diabetes, and a minority lose more and keep it off. FDA has not approved it for weight loss. The trials, doses, side effects and how it compares with Wegovy and Zepbound.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
8 min read·17 citations

Metformin causes modest weight loss: about 2% of body weight on average, against almost none on placebo, in the main long-term trial of people without diabetes.[1] It is not FDA-approved for weight loss, so using it this way is off-label.[4] The weight it takes off is small next to Wegovy or Zepbound, whose pivotal trials reported losses of about 15% and 21%,[5][6] but a minority of people on metformin lose more and keep it off, and the drug is cheap.

About this article. Written from the randomized trials and meta-analyses of metformin in people without diabetes, the current FDA label and the 2026 American Diabetes Association Standards of Care. Taking metformin alongside a GLP-1 is covered in a separate article.

How much weight do people lose on metformin?

The best long-term figures come from the Diabetes Prevention Program, a randomized trial of 3,234 adults with raised blood sugar but no diabetes and an average BMI of 34.[2] Over the two-year blinded phase, people taking metformin 850 mg twice a day lost 2.06% of their weight, against 0.02% on placebo. In the open follow-up the gap held, at 2.0% against 0.2%, and weight loss tracked with how consistently people took the drug.[1]

A 2024 meta-analysis pooled 49 randomized trials of people without diabetes who had overweight or obesity, and it reached a similar size of effect. Metformin lowered BMI by 0.56 points compared with placebo, roughly 1.6 kg for someone 5 ft 7 in tall. The authors rated the trials as low quality and found no significant difference between metformin and lifestyle change alone. Orlistat beat it.[3]

Weight change on metformin, by study
StudyWho and how longMetforminComparison
Diabetes Prevention ProgramPrediabetes, 2 years, randomized−2.06%−0.02% placebo
Follow-up of the same trialOpen label, 7 to 8 more years−2.0%−0.2% former placebo group
BIGPROAbdominal obesity, 12 months, randomized−2 kg−0.8 kg placebo
Meta-analysis, 49 trialsNo diabetes, at least 3 monthsBMI −0.56Against placebo
German clinic cohortBMI 27 or more, 6 months, not randomized−5.8 kg+0.8 kg untreated

That last row is the number often quoted online, and it deserves the least weight. The 154 patients in that clinic study were not randomized, and the 45 controls were people who declined treatment.[9][7] The BIGPRO figures come from a 2023 review in the Cleveland Clinic Journal of Medicine.[7]

An average also hides a split. After one year of the prevention trial, 28.5% of the metformin group had lost at least 5% of their weight. In a post hoc analysis, those people were still 6.2% below their starting weight in years 6 to 15, more than the comparable subgroups from lifestyle (3.7%) and placebo (2.8%).[8] The early months predict the rest fairly well: most of the loss arrives in the first 6 to 12 months.[7]

Does metformin cause weight loss if you don't have diabetes?

Yes, and that is the population nearly all of the numbers above describe. The FDA label is a different matter. Metformin is indicated only to improve blood sugar in type 2 diabetes, in adults and children 10 and older. In the label’s own 29-week diabetes trial, the metformin group lost 1.4 lb and the placebo group 2.4 lb.[4] The drug’s reputation for weight loss therefore comes from trials outside its label.

How it works is unsettled. Proposed mechanisms include lower appetite through gut hormones, changes in the gut microbiome and a rise in GDF-15, a stress hormone that reduces food intake.[7] A small 2026 trial found that the people whose GDF-15 rose most lost the most weight, and that weight drifted back toward baseline after they stopped the drug.[10] That trial enrolled 40 older people with HIV, so it is a hint and nothing firmer.

What dose of metformin is used for weight loss?

No dose has been approved for this use, because the use itself is unapproved. The trial that produced the longest data used 850 mg twice a day, or 1,700 mg daily.[2] The Cleveland Clinic review, which favors off-label use, aims for 1,500 mg a day or more, with slow increases and extended-release tablets. It reports no difference in weight loss between the immediate-release and extended-release forms.[7] The 2024 meta-analysis found no clear link between dose and effect across a range of 500 to 2,550 mg a day, so a higher dose has not been shown to mean more weight loss.[3]

The label’s diabetes dosing starts at 500 mg twice a day or 850 mg once a day with meals, and tops out at 2,550 mg a day.[4] Any dose for weight is a prescriber’s decision. Kidney function sets the limits, as the side-effects section below explains.

Who is most likely to benefit from metformin for weight?

  • People with prediabetes. Metformin cut new diabetes by 31% in the prevention trial, while lifestyle change cut it by 58%.[2] The ADA says metformin should be considered in adults at high risk, especially those aged 25 to 59 with a BMI of 35 or more.[11] How that compares with a GLP-1 is in GLP-1 drugs for prediabetes.
  • People gaining weight on antipsychotics. A 2026 network meta-analysis in JAMA Psychiatry put metformin at −3.86 kg against placebo or standard care across 16 trials, with moderate certainty. Semaglutide (−10.98 kg) and liraglutide (−5.43 kg) did better, on far fewer trials.[12] A separate meta-analysis of 20 placebo-controlled studies found −3.32 kg.[13]
  • Women with polycystic ovary syndrome. The Cleveland Clinic review lists PCOS among its priority groups.[7] The trials against newer drugs are covered in GLP-1 drugs for PCOS.
  • Children and teenagers: unclear. A 2026 Cochrane review called the metformin evidence against no treatment very uncertain, based on three studies and 151 participants.[14] In a Spanish trial of 160 children, metformin improved BMI score only in those who had not reached puberty.[15]

Does metformin work as well as Ozempic for weight?

No. No large trial has put metformin against a weight-loss dose of a GLP-1 in people without diabetes, so the comparison below crosses trials with different people and lengths, and it is a rough guide only. The gap is still wide enough that those differences are unlikely to close it.[1][5][6] One small three-month study did compare the two directly and is described in our piece on genetic testing for weight-loss drugs; semaglutide won clearly.

Average weight change in each drug's main trial (separate trials, not head to head)
Drug and trialLengthDrugPlacebo
Metformin 1,700 mg/day, Diabetes Prevention Program2 years−2.06%−0.02%
Semaglutide 2.4 mg (Wegovy), STEP 168 weeks−14.9%−2.4%
Tirzepatide 15 mg (Zepbound), SURMOUNT-172 weeks−20.9%−3.1%

Metformin’s case rests on price and track record. The 2023 review put a 90-day supply at about $10,[7] far below the cash prices in our guide to buying a GLP-1 without insurance. Its long-term data also run past 15 years, though a 2026 analysis of the same trial found that lifestyle change, not metformin, was tied to fewer chronic conditions in later life.[17] Whether metformin extends life is a separate question, taken up in metformin versus GLP-1 drugs for longevity. Our drug weight-effect lookup places metformin among other non-GLP-1 medicines.

What are the side effects of metformin for weight loss?

The stomach is the main complaint. In the diabetes trial on the label, diarrhea affected 53% of people on metformin against 12% on placebo, and nausea or vomiting 26% against 8%.[4] In the prevention trial these symptoms were more common on metformin and eased over time, and no significant safety problems emerged over the long follow-up.[1] Extended-release tablets and taking the dose after meals tend to cause fewer of them.[7]

Vitamin B12 is the slow-moving risk. In the same trial, low levels were more common on metformin at 5 years (4.3% against 2.3%), though no longer significantly so at 13 years (7.4% against 5.4%). Low or borderline-low levels were more common at both points, reaching 20.3% against 15.6%.[16] The label calls for a B12 test at intervals of 2 to 3 years.[4]

The rare serious hazard is lactic acidosis, which carries a boxed warning. Metformin must not be used with an eGFR below 30. The label’s risk factors also include age 65 or older, heavy drinking, liver impairment, surgery and contrast scans. It also names topiramate, one half of the weight-loss drug Qsymia.[4] Someone with reduced kidney function who wants to use metformin for weight should expect their prescriber to lower the dose or rule it out.[7]

Should you take metformin to lose weight?

It suits a narrow set of people: someone with prediabetes or an antipsychotic-related gain who wants a cheap, long-studied drug and would be satisfied with a few percent of body weight. The Cleveland Clinic review argues it should be seriously considered off-label, particularly in those groups, and that is expert opinion resting on the trials above.[7] Someone hoping for 10% or more is unlikely to reach it on metformin alone. The realistic test is the first year. People who had lost at least 5% by then were the ones who stayed down.[8]

Frequently Asked Questions

About 2% of body weight on average. In the Diabetes Prevention Program, people taking 850 mg twice a day lost 2.06% over two years, against 0.02% on placebo. About 28.5% lost at least 5% in the first year.
Yes, off-label. The FDA has approved metformin only for blood sugar control in type 2 diabetes, but a prescriber can legally use it for weight. Most of the weight-loss evidence comes from people without diabetes.
Weight loss generally starts after about 4 weeks and comes mainly in the first 6 to 12 months of treatment, according to a 2023 review in the Cleveland Clinic Journal of Medicine. Loss in the first year was a strong predictor of long-term results.
The evidence is thin, but it points that way. In a small 2026 trial of older people with HIV, weight moved back toward baseline after metformin stopped. In the Diabetes Prevention Program, continuing to take the drug predicted keeping the weight off.
No. Metformin averages about 2% weight loss in its main trial, while semaglutide 2.4 mg, the Wegovy dose of Ozempic's active ingredient, averaged 14.9% in STEP 1. They were separate trials. Metformin costs far less.

References

  1. 1.Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study Diabetes Care. 2012. PMID: 22442396.
  2. 2.Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med. 2002. PMID: 11832527.
  3. 3.Haber R, Zarzour F, Ghezzawi M, et al. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials Diabetes Obes Metab. 2024. PMID: 38468148.
  4. 4.Zydus Lifesciences Limited Metformin hydrochloride tablets: prescribing information (sections 1, 2, 4, 5, 6, 14) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82a10fa-1e8e-46b6-890a-737de3f34ee1
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  6. 6.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  7. 7.Rodriguez P, Pantalone KM, Griebeler ML, Burguera B Should I consider metformin therapy for weight loss in patients with obesity but without diabetes? Cleve Clin J Med. 2023. PMID: 37657834.
  8. 8.Apolzan JW, Venditti EM, Edelstein SL, et al. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study Ann Intern Med. 2019. PMID: 31009939.
  9. 9.Seifarth C, Schehler B, Schneider HJ Effectiveness of metformin on weight loss in non-diabetic individuals with obesity Exp Clin Endocrinol Diabetes. 2013. PMID: 23147210.
  10. 10.Marcelo-Calvo C, Esteban-Cantos A, Jurado F, et al. Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial Open Forum Infect Dis. 2026. PMID: 42609624.
  11. 11.American Diabetes Association Professional Practice Committee for Diabetes 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026 Diabetes Care. 2026. PMID: 41358891.
  12. 12.Stogios N, Agarwal SM, Maksyutynska K, et al. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis JAMA Psychiatry. 2026. PMID: 42418179.
  13. 13.Peng TR, Chen JA, Lee JA, et al. The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis Schizophr Bull. 2025. PMID: 39509416.
  14. 14.Gerardi C, Allocati E, Prutsky G, et al. Pharmacological interventions for the treatment of obesity in children and adolescents Cochrane Database Syst Rev. 2026. PMID: 42125960.
  15. 15.Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, et al. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial Pediatrics. 2017. PMID: 28759403.
  16. 16.Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study J Clin Endocrinol Metab. 2016. PMID: 26900641.
  17. 17.Salive ME, Tjaden AH, Ames JR, et al. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes JAMA. 2026. PMID: 42295772.

Acanthosis Nigricans: What Clears the Dark Patches, and What GLP-1s Do

Acanthosis nigricans, the dark velvety skin on the neck and armpits, usually signals high insulin. It often fades with weight loss; 86.5% cleared after sleeve gastrectomy. No trial has tested GLP-1 drugs. Metformin and cream evidence, youth risk, and when to see a doctor.

11 min read

Trulicity for Weight Loss: How Much at Each Dose

In AWARD-11, Trulicity produced about 3 kg of weight loss at 1.5 mg, 3.8 kg at 3 mg and 4.6 kg at 4.5 mg over 36 weeks in adults with type 2 diabetes. It has no weight-loss approval and no published weight trial in people without diabetes.

7 min read

Jardiance and Farxiga for Weight Loss: How Much, and Why It Stops

Jardiance and Farxiga cause about 2 kg of weight loss in type 2 diabetes and less without it, and neither is approved for weight. Why appetite cancels most of the sugar lost in urine, the side effects, and how they compare with Wegovy and Zepbound.

10 min read

Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less

Rybelsus is approved for type 2 diabetes, not weight. In its trials the 14 mg dose took off 3.1 to 4.4 kg in 26 weeks. Why the Wegovy pill does far more, what is known in people without diabetes, and why insurers won't cover it for weight.

10 min read

Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked

Ozempic, Wegovy, Rybelsus, Trulicity and Foundayo are GLP-1 receptor agonists; Mounjaro and Zepbound add GIP. Phentermine, Contrave, metformin, Jardiance, Januvia and insulin are not. 28 drugs sorted by what each FDA label calls them.

10 min read

Mounjaro Alternatives: What Costs Less and What You Give Up

Zepbound is the same drug as Mounjaro and costs $299 to $449 a month self-pay against $499. Ozempic, Trulicity, oral semaglutide and generic liraglutide cost less but did less in head-to-head trials. Compounded tirzepatide, SGLT2s and metformin.

11 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →